Actelion Ltd. is a leading biopharmaceutical company focusedon the discovery, development and commercializationof innovative drugsfor diseases with significant unmet medical needs.
Jean-Paul Clozel CEO "With the business performingbetter than anticipated, even while launching newproducts and investing in future products, I am confident to upgrade our financial guidance."
Actelion has subsidiaries in over 30 countries, covering all major pharmaceutical markets worldwide
ATLN SIX Swiss Exchange
On 09 February 2016 Actelion published the financial results for 2015 accompanied by the publication of the company's Annual Report.
The Annual General Meeting 2016 to approve the Business Report of 2015 will be held on:
WEDNESDAY, 4 MAY 2016, 10:00 A.M.
In preparing our first Sustainability Report, we chose to follow the G4 Sustainability Reporting Guidelines issued by the Global Reporting Initiative (GRI).
Please note that product information contained on this website may not necessarily comply with local product information. You are solely responsible to obtain country specific documentation.
Imprint | Legal & privacy statement | Webmaster
Copyright © 2016 Actelion Pharmaceuticals Ltd
To access local information please visit one of our affiliate sites: